Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Business shareholder activism

Artisan Partners Urges Novartis Board Shake-Up

Analysis based on 7 articles · First reported Sep 10, 2026 · Last updated Sep 10, 2026

Sentiment
-25
Attention
4
Articles
7
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard

The public activist campaign adds governance uncertainty on top of a severe share price shock for Novartis, keeping pressure on the stock and raising the risk of further board and management changes. Broader pharma and biotech sentiment may be affected as investors reassess the value of large-cap M&A pipelines and late-stage trial risk.

pharmaceuticals biotechnology asset management

Artisan Partners Asset Management, a top-20 shareholder in Swiss drugmaker Novartis, publicly called for a shake-up of the company's board to improve corporate governance and oversight of acquisitions. David Samra, managing director at Artisan Partners Asset Management and founding partner of International Value Group, said successive chairmen had failed Novartis on acquisitions and urged Chairman Bristol Myers Squibb to act, saying the board needs better talent and an acquisition committee. The call follows a record share price fall this week: on Tuesday a muscle-wasting disorder drug acquired through Novartis' $12 billion takeover of U.S. firm Avidity Biosciences failed a late-stage study, sending shares down more than 10% and wiping nearly $30 billion off market value. Shares had already fallen 3% a day earlier after heart drug pelacarsen disappointed investors. Samra also cited Novartis' 2024 acquisition of German biotech MorphoSys as disappointing, noting the company wrote down the value of that deal months later. He said he did not blame CEO Shar Narasimhan, who has led Novartis since 2018, and instead questioned whether the board exercised sufficient scrutiny over deals. Samra also urged the board to overhaul Novartis' compensation structure, saying it relies too heavily on adjusted performance measures that exclude writedowns. Novartis said its financial guidance was unchanged by the recent setbacks and that it has a broad pipeline of medicines, adding it continues a disciplined and shareholder-friendly approach to capital allocation. Artisan is the first investor to publicly call for board changes, though others have voiced concerns about Novartis' M&A strategy.

90 Novartis failed late-stage study
85 Artisan Partners Asset Management called for board shake-up Novartis
70 Novartis disappointed investors
60 David Samra urged board overhaul Novartis
45 Novartis acquired MorphoSys
40 Novartis reaffirmed guidance
stock
Central subject of the event; its shares suffered a record fall after back-to-back trial setbacks and it now faces public shareholder pressure for board and governance changes.
Importance 100.0 Sentiment -45.0
stock
Top-20 Novartis shareholder that publicly launched the board shake-up campaign, positioning itself as the leading activist voice on Novartis governance.
Importance 85.0 Sentiment 10.0
per
Artisan Partners Asset Management managing director who led the public call for board changes, criticized Novartis' acquisition track record, and urged compensation reform.
Importance 80.0 Sentiment 5.0
per
Novartis chairman directly urged by David Samra to make board-level changes and improve oversight of acquisitions.
Importance 60.0 Sentiment -20.0
per
Novartis CEO whose tenure is seen as a test amid the trial setbacks, though Samra explicitly did not blame him for the failures.
Importance 55.0 Sentiment -10.0
stock
U.S. firm acquired by Novartis for $12 billion whose muscle-wasting disorder drug failed a late-stage study, triggering the share slump.
Importance 50.0 Sentiment -30.0
stock
German biotech acquired by Novartis in 2024 and later written down, cited by Samra as evidence of a poor acquisition track record.
Importance 35.0 Sentiment -20.0
cnt
Home country of Novartis; the governance controversy at its largest drugmaker may weigh on Swiss market sentiment.
Importance 15.0 Sentiment -5.0
cnt
Home country of Avidity Biosciences and Artisan Partners Asset Management, both central to the acquisition and activist campaign.
Importance 10.0 Sentiment 0.0
Novartis related ↔ Switzerland
Novartis related ↔ United States
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.